ホーム › 急性骨髄性白血病 › ニューヨーク

ニューヨークにおける急性骨髄性白血病の臨床試験

ニューヨーク内の拠点で、急性骨髄性白血病に関する71件の研究が参加者を募集しています。

ニューヨーク内の都市

公式研究テキスト（英語）

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Montefiore Medical Center - Moses Campus /ID# 279399, The Bronx

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/10/02更新 · NCT07581002

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo

被験者募集中第2相

60歳以上 · 全性別 · 2026/10/02更新 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Cancer Center, New York
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06484062

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1相

12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Mount Sinai Hospital, New York
他5件

被験者募集中第2相

18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Roswell Park Comprehensive Cancer Center, Buffalo
Memorial Sloan Kettering Cancer Center, New York
New York Presbyterian - Weill Cornell, New York
他2件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Northwell Health/Center for Advanced Medicine, Lake Success
他9件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Roswell Park Cancer Institute, Buffalo

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/24更新 · NCT06871410

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1相

21歳以下 · 全性別 · 2026/09/23更新 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Northwell Health/Center for Advanced Medicine, Lake Success
他5件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

A Study of CRD3874-SI in People With Leukemia

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All protocol activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07661095

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
他4件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
他9件

被験者募集中第2相

18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/09/18更新 · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
他11件

被験者募集中第3相

6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Montefiore Medical Center, New York

被験者募集中第1/2相

30 Days · 全性別 · 2026/09/16更新 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Weill Cornell, New York
Clinical Research Allicance, Westbury

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168

A Telehealth Advance Care Planning Intervention

University of Rochester, Rochester

被験者募集中

60歳以上 · 全性別 · 2026/09/11更新 · NCT05875805

Cord Blood Transplant in Adults With Blood Cancers

Memorial Sloan Kettering Cancer Center, New York

被験者募集中第2相

21歳〜65歳 · 全性別 · 2026/09/11更新 · NCT05884333

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Roswell Park Comprehensive Cancer Center, Buffalo

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/11更新 · NCT06969430

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

New York Medical College /ID# 275597, Valhalla

被験者募集中第1相

6 Months – 17 Years · 全性別 · 2026/09/09更新 · NCT07306832

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Albany Medical Center, Albany
Montefiore Medical Center - Moses Campus, The Bronx

被験者募集中第3相

1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/25更新 · NCT06533761

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
他7件

被験者募集中第1/2相

22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center - New York, New York
Cohen Children's Medical Center, Queens

被験者募集中第3相

29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

State University of New York at Buffalo, Buffalo
Icahn School of Medicine at Mount Sinai, New York
Columbia University, New York
他1件

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

Stony Brook Cancer Center, Stony Brook

被験者募集中観察研究

18歳以上 · 全性別 · 2026/08/20更新 · NCT06297551

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Roswell Park Comprehensive Cancer Center, Buffalo
Northwell Health, LLC PRIME, Lake Success
Memorial Sloan Kettering Cancer Center, New York
他3件

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NYU Langone Health, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/18更新 · NCT06656494

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

New York Presbyterian Hospital-Columbia University Medical Center, New York

被験者募集中第4相

18歳以上 · 全性別 · 2026/08/11更新 · NCT07486713

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Memorial Sloan- Kettering Cancer Center, New York

被験者募集中第1相

1歳〜30歳 · 全性別 · 2026/08/03更新 · NCT06177067

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Research Site, New York

被験者募集中第1/2相

16歳以上 · 全性別 · 2026/07/20更新 · NCT07155226

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

University of Rochester Medical Center (URMC), Rochester

被験者募集中第3相

18歳〜75歳 · 全性別 · 2026/07/17更新 · NCT05429632

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第2相

60歳以上 · 全性別 · 2026/07/17更新 · NCT07392242